WARMINSTER, Pa., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive ...

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma has reported that their RNAi therapeutic candidate, imdusiran, combined with a short course of interferon, has achieved a functional ...

The Journal of the American Medical Association (JAMA) stated on March 10 that between 1.6 million and 2.4 million Americans live with chronic hepatitis B virus (CHBV). New recommendations released ...

Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially ...

WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS), a key player in advancing treatments for chronic hepatitis B (cHBV), outlined its progress in Q1 2025, showcasing pivotal clinical ...

WARMINSTER, PA — Arbutus Biopharma Corporation (NASDAQ: ABUS) has unveiled its strategic objectives for 2025 alongside an encouraging financial update, emphasizing progress in its efforts to develop a ...

WARMINSTER, Pa., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and ...

The positions in the table below reflect the Centro Hospitalar do Baixo Vouga (CHBV)'s position overall, domestically, within their sector, and in various subject areas based on their Share. Each ...

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved ...